Cargando…

Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study

BACKGROUND: In contrast to vitamin K antagonists (VKA), direct oral anticoagulants (DOAC's) are not strictly monitored and dose titrated by anticoagulation clinics in the Netherlands. This may affect drug persistence of atrial fibrillation (AF) patients, whom often require lifelong treatment. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zielinski, Gilda Denise, van Rein, Nienke, Teichert, Martina, Klok, Frederikus A., Rosendaal, Frits R., van der Meer, Felix J. M., Huisman, Menno V., Cannegieter, Suzanne C., Lijfering, Willem M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles: Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971315/ https://www.ncbi.nlm.nih.gov/pubmed/31989096 http://dx.doi.org/10.1002/rth2.12261

Ejemplares similares

Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda D., et al.
Publicado: (2021)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Risk prediction of recurrent venous thrombosis; where are we now and what can we add?
por: Timp, Jasmijn F., et al.
Publicado: (2019)

Predicting the risk of recurrent venous thrombosis: What the future might bring
por: Lijfering, Willem M., et al.
Publicado: (2019)

The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk
por: Khialani, Deeksha, et al.
Publicado: (2020)

Glucose levels and diabetes are not associated with the risk of venous thrombosis: results from the MEGA case‐control study
por: Li‐Gao, Ruifang, et al.
Publicado: (2018)

Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma
por: Kaptein, Fleur H. J., et al.
Publicado: (2022)

Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower‐leg injury or knee arthroscopy
por: Mohammed, Yassene, et al.
Publicado: (2022)

Glucocorticoid use and risk of first and recurrent venous thromboembolism: self‐controlled case‐series and cohort study
por: Orsi, Fernanda A., et al.
Publicado: (2021)

Factor V levels and risk of venous thrombosis: The MEGA case‐control study
por: Rietveld, Inge M., et al.
Publicado: (2018)

Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial
por: Orsi, Fernanda A., et al.
Publicado: (2019)

Procoagulant factors and future risk of arterial cardiovascular disease in patients with prior venous thrombosis: A cohort study
por: Yap, Eng Soo, et al.
Publicado: (2023)

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Camilleri, Eleonora, et al.
Publicado: (2021)

Detection of upper extremity deep vein thrombosis by magnetic resonance non‐contrast thrombus imaging
por: van Dam, Lisette F., et al.
Publicado: (2021)

Effect of gender‐affirming hormone use on coagulation profiles in transmen and transwomen
por: Scheres, Luuk J.J., et al.
Publicado: (2021)

Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands
por: Chen, Qingui, et al.
Publicado: (2023)

Procoagulant factor levels and risk of venous thrombosis in the elderly
por: Wang, Huijie, et al.
Publicado: (2020)

Risk of recurrence in women with venous thromboembolism related to estrogen‐containing contraceptives: Systematic review and meta‐analysis
por: Wiegers, Hanke M. G., et al.
Publicado: (2022)

Safety of using the combination of the Wells rule and D‐dimer test for excluding acute recurrent ipsilateral deep vein thrombosis
por: van Dam, Lisette F., et al.
Publicado: (2020)

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD‐AF registry
por: Seelig, Jaap, et al.
Publicado: (2020)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Quality of life and functional limitations after pulmonary embolism and its prognostic relevance
por: Keller, Karsten, et al.
Publicado: (2019)

Coagulation factors II, V, VII, IX, X and XI and mortality – a cohort study
por: Yap, Eng Soo, et al.
Publicado: (2023)

Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients
por: Stals, Milou A. M., et al.
Publicado: (2021)

Endogenous sex hormones and risk of venous thromboembolism in young women
por: Scheres, Luuk J. J., et al.
Publicado: (2019)

Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts
por: den Exter, Paul L., et al.
Publicado: (2020)

Growth differentiation factor‐15 for prediction of bleeding in cancer patients
por: Mulder, Frits I., et al.
Publicado: (2021)

The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment
por: Kooiman, Judith, et al.
Publicado: (2015)

Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease
por: Kooiman, Judith, et al.
Publicado: (2014)

Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review
por: van der Wall, Sake J., et al.
Publicado: (2018)

Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants
por: Lee, Jeffrey, et al.
Publicado: (2022)

Anti‐β2‐glycoprotein I and anti‐prothrombin antibodies cause lupus anticoagulant through different mechanisms of action
por: Noordermeer, Tessa, et al.
Publicado: (2021)

Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study
por: Giustozzi, Michela, et al.
Publicado: (2021)

Sex‐specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants—A substudy of the EINSTEIN‐PE study
por: Wiegers, Hanke M. G., et al.
Publicado: (2021)

Defective fibrin deposition and thrombus stability in Bambi (−/−) mice are mediated by elevated anticoagulant function
por: Crawley, James T. B., et al.
Publicado: (2019)

Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism
por: Boon, Gudula J. A. M., et al.
Publicado: (2020)

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
por: Pasternack, Ralf, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s0ks1fc6oqgsjmgghle5sbk0vs